Key facts
- This page summarizes Christopher J. Bilotto's Form 4 filing for DIVERSIFIED HEALTHCARE TRUST (:DHC).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 12 Jun 2026, 16:21.
Christopher J. Bilotto - 10 Jun 2026 Form 4 Insider Report for DIVERSIFIED HEALTHCARE TRUST (:DHC)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- :DHC
- Reported as of
- 10 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Jun 2026, 16:21:52 UTC
- Prior SEC filing
- 02 Apr 2026
- Next SEC filing
- 12 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher J. Bilotto
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher J. Bilotto filed Form 4 for DIVERSIFIED HEALTHCARE TRUST (:DHC) on 12 Jun 2026.
Change
- Previous filing in this sequence was filed on 02 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001806557
Primary reporting owner
Bilotto Christopher J.
- Relationship
- President and CEO, Director
- Address
- C/O THE RMR GROUP LLC, TWO NEWTON PL., 255 WASH. ST., STE. 300, NEWTON
- Signature
- /s/ Christopher J. Bilotto
- Signature date
- 12 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
:DHC
transaction
Common Shares of Beneficial Interest
Award
- Transaction value
- Shares
- +12,401
- Change %
- +4.6%
- Price
- Shares after
- 279,247
- Date
- 10 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Transaction reported is award of shares pursuant to the Issuer's equity compensation plan.
Footnote F2
Includes 560.894 shares acquired under a dividend reinvestment plan since the last Section 16 filing by Mr. Bilotto.